HIGHLIGHTS
- who: Jean-Matthieu Lu2019Orphelin and collaborators from the Department of Dermatology, Caen-Normandie University Hospital, Caen , France have published the Article: Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma, in the Journal: Cancers 2023, 2170 of 31/08/2020
- what: The authors focused on terms related to ICIs used in melanoma only (anti-PD-1 antibodies (nivolumab and pembrolizumab) and anti-CTLA-4 antibodies (ipilimumab)) in the title or abstract (or both) that were considered the sole research domain, and the search strategy included the Cochrane Highly Sensitive Search Strategy for identifying RCTs . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.